Peripheral Blood Stem Cell Autografts Research Articles

Cardiopulmonary Complications Observed in Children Undergoing Peripheral Blood Stem Cell Autografts

Cardiopulmonary Complications Observed in Children Undergoing Peripheral Blood Stem Cell Autografts

Recovery of Hematopoiesis after High-dose Chemotherapy and Peripheral Blood Stem Cell Autografts in Children

Recovery of Hematopoiesis after High-dose Chemotherapy and Peripheral Blood Stem Cell Autografts in Children

Early Infectious Complications in Children Undergoing Peripheral Blood Stem Cell Autografts without a Strict Aseptic Procedure

Early Infectious Complications in Children Undergoing Peripheral Blood Stem Cell Autografts without a Strict Aseptic Procedure

Evaluations of the Growth and Endocrine Functions in Children after High-dose Chemotherapy and Peripheral Blood Stem Cell Autografts

Evaluations of the Growth and Endocrine Functions in Children after High-dose Chemotherapy and Peripheral Blood Stem Cell Autografts

Early infectious complications after peripheral blood stem cell autografts in children

Seventeen children underwent marrow-ablative high-dose chemotherapy with peripheral blood stem cell autografts and were studied retrospectively to determine the type, frequency, and outcomes associated with infectious complications 3 months postgraft. The patients were kept in isolated rooms with a laminar air flow facility, but no decontamination procedures, such as gut sterilization with nonabsorbable antibiotics, nonmicrobial diet, and skin cleansing, were used. They were under their mothers' daily care to maintain good psychological conditions. After the completion of marrow-ablative chemotherapy and the infusion of stem cells, the absolute granulocyte count exceeded 0.5 x 10(9)/liter with a mean of 17.9 days (range 6-65 days). Fifteen patients developed a total of 16 febrile episodes during the first 4 week period, and the confirmed diagnoses were mucositis (12), enterocolitis (nine), septicemia (four), central venous catheter-associated infection (three), pneumonia (one), perianal abscess (one), and possible invasive fungal infection (one). All episodes were successfully treated with parenteral antibiotic therapy, and no patient died of infectious complications. The observations suggest that high-dose chemotherapy can be performed safely with simple and efficient patient management protocol followed by peripheral blood stem cell autografts.

Peripheral Blood Stem Cell Autografts in Children with Acute Lymphoblastic Leukemia and Lymphoma: Updated Experience.

Peripheral blood stem cells (PBSC) in autografts (PBSCT) were given to 16 children with high-risk acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL). Harvest of PBSC is a safe, reliable procedure with low morbidity in children with cancer, and cryopreserved PBSC are useful in reducing cytopenia following marrow-ablative chemotherapy. The CFU-GM content of the thawed grafts is an important determinant of hematopoietic recovery after PBSCT. Whereas not all collections from children who had received intensive chemotherapy yielded sufficient progenitors for a safe graft, the value of preleukapheresis use of granulocyte colony-stimulating factor to expand the transplantable stem cell pool was not proven. After marrow-ablative chemotherapy without total body irradiation, three children who underwent PBSCT at refractory relapse died within 3 months. However, eight of the remaining 13 children are currently alive and disease-free, 5-29 months after PBSCT.

FOLINIC ACID AND PERIPHERAL BLOOD STEM CELL COLLECTION IN PATIENTS WITH ACUTE LEUKAEMIA

British Journal of HaematologyVolume 77, Issue 1 p. 127-128 Free Access FOLINIC ACID AND PERIPHERAL BLOOD STEM CELL COLLECTION IN PATIENTS WITH ACUTE LEUKAEMIA J. Reiffers, J. Reiffers Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorC. Marit, C. Marit Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorP. Cony-Makhoul, P. Cony-Makhoul Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorC. Foures, C. Foures Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorPh. Bernard, Ph. Bernard Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorG. Vezon, G. Vezon Bone Marrow Transplant Unit, Service des Maladies du Sang, Hôpital Saint Antoine, URBB INSERM 263Search for more papers by this authorJ. Ph. Laporte, J. Ph. Laporte Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorJ. Y. Mary, J. Y. Mary Université Paris 7, Paris, France Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorN. C. Gorin, N. C. Gorin Bone Marrow Transplant Unit, Service des Maladies du Sang, Hôpital Saint Antoine, URBB INSERM 263Search for more papers by this author J. Reiffers, J. Reiffers Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorC. Marit, C. Marit Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorP. Cony-Makhoul, P. Cony-Makhoul Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorC. Foures, C. Foures Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorPh. Bernard, Ph. Bernard Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorG. Vezon, G. Vezon Bone Marrow Transplant Unit, Service des Maladies du Sang, Hôpital Saint Antoine, URBB INSERM 263Search for more papers by this authorJ. Ph. Laporte, J. Ph. Laporte Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorJ. Y. Mary, J. Y. Mary Université Paris 7, Paris, France Bone Marrow Transplant Unit, CHR Bordeaux, France.Search for more papers by this authorN. C. Gorin, N. C. Gorin Bone Marrow Transplant Unit, Service des Maladies du Sang, Hôpital Saint Antoine, URBB INSERM 263Search for more papers by this author First published: January 1991 https://doi.org/10.1111/j.1365-2141.1991.tb07962.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES Laporte, J.P., Douay, L. & Allieri, A. (1990) Expansion by folinic acid of the peripheral blood progenitor pool alter chemotherapy: its use in autografting in acute leukaemia. British Journal of Haematology, 74, 445– 451. Laporte, J.P., Gorin, N.C. & Fechtenbaum, J. (1987) Relapse after autografting with peripheral blood stem cells. (Letter). Lancet, ii, 1393. Reiffers, J., Vezon, G. & Bernard, Ph. (1988) Stem cell apheresis in patients with acute nonlymphocytic leukemia. Plasma Therapy and Transfusion Technology, 9, 115– 118. Siena, S., Bregni, M., Brando, B., Ravagnani, F., Bonadonna, G. & Gianni, M. (1989) Circulation of CD 34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood, 74, 1905– 1914. To, L.B., Haylock, D.N., Kimber, R.J. & Juttner, C.A. (1984) High levels of circulating haematopoietic stem cells in very early remission from acute non-lymphocytic leukaemia and their collection and cryopreservation. British Journal of Haematology, 58, 399– 410. Anon. (1989) Proceedings of the International Symposium on Peripheral Blood Stem Cell Autografts (15–17 October 1989, Mulhouse. France). Bone Marrow Transplantation, 5 (Suppl. 1). Laporte, J.Ph., Douay, L., Allien, A., et al (1990) Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. British Journal of Haematology, 74, 445– 451. Laporte, J.Ph., Gorin, N.C. & Fechtenbaum, J. (1987) Relapse after autografting with peripheral blood stem cells. (Letter). Lancet, ii, 93. Reiffers, J., Marit, G., David, B., Bernard, Ph. & Broustet, A. (1988) Autologous stem cell transplantation in acute myeloid leukaemia. (Letter). Lancet, i, 419. Citing Literature Volume77, Issue1January 1991Pages 127-128 ReferencesRelatedInformation

Peripheral Blood Stem Cell Autografts (PBSCT) for the Treatment of 30 Children with Acute Leukemias and Lymphoma

Peripheral Blood Stem Cell Autografts (PBSCT) for the Treatment of 30 Children with Acute Leukemias and Lymphoma

Peripheral blood stem cell (PBSC) autograft for 26 children with acute leukemia or lymphoma

Peripheral blood stem cell (PBSC) autograft for 26 children with acute leukemia or lymphoma

Increased numbers of circulating haematopoietic progenitor cells after treatment with high‐dose interleukin‐2 in cancer patients

Immunotherapy with recombinant interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells has been applied to patients with metastatic cancers for its antitumour activity. In the present study we investigated the effects of in vivo administration of IL-2 (3 x 10(6) U/m2/d, continuously i.v.) on haematopoiesis. Six patients with disseminated renal cell carcinoma, treated with IL-2 and LAK cells, were monitored for the numbers of white blood cells and circulating haematopoietic progenitor cells (HPC). During IL-2 treatment lymphopenia developed, followed by lymphocytosis after discontinuation of IL-2 infusions. IL-2 administration also resulted in neutrophilia and eosinophilia. Absolute numbers of circulating HPC declined markedly during IL-2 treatment. However, after completing IL-2 infusions, the numbers of circulating erythroid (BFU-E), myeloid (CFU-GM) and multipotential progenitor cells (CFU-GEMM) strongly increased, reaching a maximum after 5 d (day 10 from the start of IL-2 treatment). This increase did not result from repeated leucaphereses, since patients treated with IL-2 alone showed a similar response. In comparison with pretreatment levels the pool of circulating HPC expanded about 20-fold. This study illustrates that IL-2 treatment has a biphasic effect on the frequency of circulating BFU-E, CFU-GM and CFU-GEMM, causing a decrease during IL-2 infusion, followed by an increase after IL-2 administration. The total number of progenitor cells harvested by four consecutive leucaphereses is in the range that is commonly used for peripheral blood stem cell autografting.

PERIPHERAL BLOOD STEM CELL AUTOGRAFTING: A NEW THERAPEUTIC OPTION FOR AML?

British Journal of HaematologyVolume 66, Issue 3 p. 285-288 PERIPHERAL BLOOD STEM CELL AUTOGRAFTING: A NEW THERAPEUTIC OPTION FOR AML? L. B. To, L. B. To Leukaemia Research Unit, Division of Haematology, Institute of Medical and Veterinary Science and the Clinical Haematology Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaSearch for more papers by this authorC. A. Jutiner, Corresponding Author C. A. Jutiner Leukaemia Research Unit, Division of Haematology, Institute of Medical and Veterinary Science and the Clinical Haematology Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaDr C. A. Juttner, Division of Haematology. Institute of Medical and Veterinary Science, PO Box 14. Rundle Street, Adelaide, South Australia, Australia 5000.Search for more papers by this author L. B. To, L. B. To Leukaemia Research Unit, Division of Haematology, Institute of Medical and Veterinary Science and the Clinical Haematology Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaSearch for more papers by this authorC. A. Jutiner, Corresponding Author C. A. Jutiner Leukaemia Research Unit, Division of Haematology, Institute of Medical and Veterinary Science and the Clinical Haematology Unit, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaDr C. A. Juttner, Division of Haematology. Institute of Medical and Veterinary Science, PO Box 14. Rundle Street, Adelaide, South Australia, Australia 5000.Search for more papers by this author First published: July 1987 https://doi.org/10.1111/j.1365-2141.1987.00055.x-i1Citations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat Citing Literature Volume66, Issue3July 1987Pages 285-288 RelatedInformation

Peripheral blood stem cell autografting.

Transplantation of haemopoietic stem cells provides a means whereby patients with malignant disease may be treated with increased doses of chemotherapy or chemoradiotherapy. Until recently, the bone marrow has been the sole source of these cells. However, haemopoietic progenitors can also be demonstrated in the blood and it has been known for more than twenty years that peripheral blood mononuclear cells are capable of repopulating the marrow in animals. This phenomenon has recently been reproduced in man. The use of peripheral blood rather than bone marrow for autologous stem cell rescue may have advantages in terms of ready access, availability in patients with compromised pelvic bone marrows, a lower risk of tumour contamination and more rapid granulocyte and immune recovery. However, clinical experience with peripheral blood stem cell autografting is still very small. This review discusses the characteristics of circulating stem cells, the methods by which they can be collected and stored and the information which has come from recent studies of their transplantation in man.